Scleroderma

Clinical Features: Criteria for Systemic sclerosis 2013 ACR/EULAR Classification Criteria for Scleroderma were developed by the American College of Rheumatology(ACR) and the European League Against Rheumatism(EULAR).Twenty-three candidate items were considered.They were reduced by clustering items and simplifying weights and was then tested by comparing performance in scleroderma patients and control patients, and validated with a group of experts.Skin thickening of the fingers extending proximal

1970 Date of Death: March 30, 2012 Place of Death: Cause of death: Progressive systemic scleroderma 1. Etiology – Progressive systemic scleroderma is a disease in which the immune system begins to attack the body. Suddenly the immune system starts to think that the healthy tissue in the body is harmful and begins to destroy them. There are many different types of this disease and progressive systemic scleroderma affects each person differently. It is considered an autoimmune disorder or disease. Many

Scleroderma is a broad term used to describe a spectrum of disorders identified by skin fibrosis (Succaria, Kurban, Kibbi & Abbas, 2013). It is a serious condition that is classified as either being a systemic or localised autoimmune disease of collagen tissue impacting both internal and external organs (Oksel & Gündüzoğlu, 2014). Due to the vast divergency of this disease there will be brief discussion on the various forms of both systemic and localised scleroderma however, the main focus is to

known as, scleroderma or CREST syndrome is a chronic inflammatory, autoimmune connective tissue disease. Scleroderma is a connective tissue disease that involves changes in the skin, blood vessels, muscles, and internal organs. This disease can be classified into two main types, systemic or localized. Systemic scleroderma can affect all parts of the body, such as internal organs, skin, and blood vessels. Localized only affects the skin and is not life threatening, as systemic can be. Scleroderma can be

Classification Criteria. EUSTAR Congress 2016. In press 4. Sáez-Comet L et al. Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. J Rheumatol. 2015; 42(12): 2327-31. 5. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nature Reviews Disease Primers. 2015; 1:1-21. 6. LeRoy EC, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988; 15: 202–205. 7. Hasegawa M. Biomarkers in systemic sclerosis: Their

down the observed conditions to really determine the best treatment options for our patient. The condition I got to research is called “scleroderma.” When you look at the disorder itself, we can see the two Greek words: sclero and derma. With “sclero” meaning hard, and “derma” meaning skin, we can come to presume that scleroderma is the hardening of skin. Scleroderma, also called Progressive Systemic Sclerosis, is a chronic connective tissue disease in which excessive amounts of collagen are rapidly

Scleroderma Scleroderma literally means “hard skin.” More women than men have the disease. The case can be mild or severe and doctors diagnose it using the patient’s medical history, skin biopsy, lab tests, and a physical exam. Scleroderma is a disease in which the body’s immune system works against itself. With scleroderma the skin sees it’s own tissues as foreign antibodies and actively tries to destroy it, making collagen like it does when there is a present injury. Instead of stopping to produce

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. A clinical trial was performed to verify the effectiveness and tolerability of low-dose imatinibon (Tyrosine kinase inhibitors that may be a therapeutic option for SSc patients) interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. Due to published clinical trails that were inconclusive about imatinib effectiveness

career plans to take me to doctor visits and provide me with all the extra medical care needed. Both of my parents have always been there to support and guide me, especially in the difficult times. At the age of three, I was diagnosed with scleroderma. Scleroderma is a chronic connective tissue disease that involves the hardening and tightening of the skin and connective tissues. This disease has made life goals more challenging and difficult to accomplish. But I believe has given me more strength

Scleroderma, also named Systemic Sclerosis (SSc) is considered a rare systemic connective tissue disease affecting mainly the skin and vascular system in the form of generalized microvascular obliterative lesions affecting mainly the small and medium sized vessels (Black 1995). Current thinking of SSc vascular disease suggests an autoimmune contribution, chemical modifications of the endothelium and a possible viral trigger were proposed (Pandey and Leroy 1998). In SSc, an imbalance in endothelial